- Home
- ACRS vs SPCE Comparison
ACRS vs SPCE Comparison
Compare ACRS & SPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | SPCE |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 430.5M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ACRS | SPCE |
|---|---|---|
| Price | $3.33 | $2.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 7 |
| Target Price | ★ $10.18 | $3.51 |
| AVG Volume (30 Days) | 3.5M | ★ 5.4M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | 60.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,683,000.00 | $1,544,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22,960.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.93 | $2.13 |
| 52 Week High | $6.60 | $8.90 |
Technical Indicators
Market Signals| Indicator | ACRS | SPCE |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 28.78 |
| Support Level | $3.16 | $2.38 |
| Resistance Level | $3.44 | $2.68 |
| Average True Range (ATR) | 0.33 | 0.13 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 6.31 | 5.13 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.